Purevax Rabies
rabies recombinant canarypox virus (vCP65)
Table of contents
Overview
Purevax Rabies is a veterinary vaccine used to protect cats from 12 weeks of age against rabies infection. It contains rabies recombinant canarypox virus (vCP65).
This EPAR was last updated on 17/02/2021
Authorisation details
Product details | |
---|---|
Name |
Purevax Rabies
|
Agency product number |
EMEA/V/C/002003
|
Active substance |
vCP65 virus
|
International non-proprietary name (INN) or common name |
rabies recombinant canarypox virus (vCP65)
|
Species |
Cats
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI06AX
|
Publication details | |
---|---|
Marketing-authorisation holder |
Boehringer Ingelheim Vetmedica GmbH
|
Revision |
7
|
Date of issue of marketing authorisation valid throughout the European Union |
18/02/2011
|
Contact address |
Product information
14/08/2020 Purevax Rabies - EMEA/V/C/002003 - IG/1279
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Immunologicals
Therapeutic indication
Therapeutic indication
Active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection.
Onset of immunity: 4 weeks after the primary vaccination course.
Duration of immunity after primary vaccination: 1 year.
Duration of immunity after revaccination: 3 years.